Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 31;14:2293–2300. doi: 10.2147/OTT.S298679

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

LHFPL3-AS1 knockdown inhibits OSCC development and cisplatin resistance. (A) Relative expression of LHFPL3-AS1 after transfection with siRNAs. (B) CCK8 assay for cell proliferation analysis. (C) Relative colony formation was determined to analyze cell proliferation. (D) Cell cycle distribution was analyzed. (E and F) Cell migration and invasion analyses by Transwell assay. (G) Relative expression of LHFPL3-AS1 in cisplatin-resistant cell lines after transfection of siRNAs. (H) Cell proliferation potential of SCC9-R and CAL27-R cells was assessed in the presence of cisplatin after transfection with siRNAs. *P<0.05.